Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Boehringer Ingelheim
Cantor Fitzgerald
Covington
US Department of Justice
Medtronic
Baxter
Chubb

Generated: May 25, 2018

DrugPatentWatch Database Preview

NEBCIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Nebcin patents expire, and what generic alternatives are available?

Nebcin is a drug marketed by Lilly and is included in four NDAs.

The generic ingredient in NEBCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
Summary for NEBCIN
Drug patent expirations by year for NEBCIN
Synonyms for NEBCIN
(1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside
(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside
(2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahyd
(2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol; sulfuric acid
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol; sulfuric acid
(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
1-Epitobramycin
1-Epitobramycin sulfate
11098-01-4
11111-45-8
3'-Deoxykanamycin B
32986-56-4
34337-51-4
37321-13-4
4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine
4-AMINO-2-[4,6-DIAMINO-3-(3-AMINO-6-AMINOMETHYL-5-HYDROXY-TETRAHYDRO-PYRAN-2-YLOXY)-2-HYDROXY-CYCLOHEXYLOXY]-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL
49842-07-1
49842-07-1 (Sulfate)
54330-95-9
70322-33-7
842T071
986T564
A-8891
AB00052438_13
AB00052438_14
AB00052438-12
AB00513858
AB2000616
AC1L1VI0
AC1L1WB7
AC1Q2AOW
AK481288
AKOS016339662
AKOS025310614
Aktob
AN-41518
AN-9578
AOB5629
API0004434
API0004435
BC655154
BDBM50366778
Bethkis (TN)
BIDD:GT0503
BIT0153
BIT0802
BPBio1_000647
BRN 1357507
Brulamycin
BSPBio_000587
BSPBio_002036
C-22669
C00397
C18H37N5O9
C18H39N5O13S
CA002928
CA006492
CA009438
CAS-32986-56-4
CC-35084
CCG-39936
CHEBI:28864
CHEMBL1200780
CHEMBL1747
CPD000058793
CS-2547
CTK8G3501
D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribohexopyranosyl-(1->4)]-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4))-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-
D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-, sulfate (2:5)(salt)
D00063
DB00684
Deoxykanamycin B
Distobram
DR002903
DSSTox_CID_3680
DSSTox_GSID_23680
DSSTox_RID_77144
DTXSID8023680
EINECS 251-322-5
EINECS 256-499-2
Gernebcin
Gotabiotic
HMS2090B16
HMS2092M17
HMS2096N09
HMS2230J04
HSDB 3259
HY-B0441
J10405
K412
KBio2_001552
KBio2_004120
KBio2_006688
KBio3_001536
KBioGR_001104
KBioSS_001552
KM1982
KS-1405
Lilly 47663
LS-146940
LS-146941
LS-187329
MFCD00077885
MLS000069544
MLS000069826
MolPort-003-665-548
MolPort-006-108-157
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
Nebcin (Sulfate)
Nebicin
Nebicina
NEBRAMYCIN
Nebramycin 6
Nebramycin factir 6
Nebramycin factor 6
Nebramycin VI
Nebramycin-Faktor 6
NF 6
NLVFBUXFDBBNBW-PBSUHMDJSA-N
NSC 180514
NSC-757352
NSC757352
O-?3-?AMINO-?3-?DEOXY-?ALPHA-?D-?GLUCOPYRANOSYL-?(1?6)-?O-?[2,?6-?DIAMINO-?2,?3,?6-?TRIDEOXY-?ALPHA-?D-?RIBO-?HEXOPYRANOSYL-?(1?4)]-?2-?DEOXY-?D-?STREPTAMINE
O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-->4)]-2-deoxy-D-streptamine
O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-?-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-?-D-ribohexopyranosyl-(1-4)]-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-a -D-ribo-hexopyranosyl-(1-4)]-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-6))-2-deoxy-L-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Obracine
Obramycin
Opera_ID_1050
Pharmakon1600-01500579
Prestwick3_000544
Q-201837
Q-201838
ro-2H-pyran-3,5-diol
s2514
SAM001246911
SBI-0051915.P003
SC-45657
SCHEMBL2837
SCHEMBL2838
SMR000058793
SMR000058891
SPBio_000295
Spectrum_001072
SPECTRUM1500579
Spectrum2_000078
Spectrum3_000588
Spectrum4_000752
Spectrum5_001038
SPRC-AB01
SR-05000001726
SR-05000001726-2
ST24050180
Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-
Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-
Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-, D-, sulfate (salt)
SULFURIC ACID; TOBRAMYCIN
Sybryx
Tenebrimycin
Tenemicin
Tenemycin
TOA-(1-6)2TB-(4-1)TOC
TOA-(1-6)TOB-(4-1)TOC
Tobacin
Tobi
Tobi (TN)
Tobi Podhaler
Tobra
Tobracin
Tobracin (TN)
Tobradex
Tobradistin
Tobralex
Tobramaxin
Tobramicin
Tobramicina
Tobramicina [INN-Spanish]
Tobramitsetin
Tobramycetin
tobramycin
Tobramycin (JP17/USP)
Tobramycin [USAN:BAN:INN:JAN]
Tobramycin Base
Tobramycin for Inhalation
tobramycin solution for inhalation
TOBRAMYCIN SULFATE
Tobramycin sulfate salt
Tobramycin sulfate salt, aminoglycoside antibiotic
Tobramycin, Antibiotic for Culture Media Use Only
Tobramycine
Tobramycine [INN-French]
Tobramycinum
Tobramycinum [INN-Latin]
Tobrased
Tobrasone
Tobrex
Tobrex (TN)
torbamycin
Tox21_110626
TOY
UNII-VZ8RRZ51VK
vantobra
VZ8RRZ51VK
ZEUUPKVZFKBXPW-TWDWGCDDSA-N
ZINC8214692
ZX-AFC000193
ZX-AFC000509

US Patents and Regulatory Information for NEBCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 050519-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 050477-005 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 062008-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 062707-001 Apr 29, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Teva
Citi
Argus Health
Deloitte
Queensland Health
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.